Duravest, Inc. Announces Initial Appointments to its Scientific Advisory Board.

CHICAGO -- Duravest, Inc. (OTC BB:DUVT, XETRA:DUV) is a publicly traded holding company that initiates and develops strategic investments in leading edge medical technologies. Duravest has assembled a world-class medical and scientific advisory board to support the company's unique expertise in cross-disciplinary technology development and to assist its subsidiaries in their clinical trial and market development. Duravest is pleased to announce the appointments of Dr. Alex Norbash and Prof. Lisa Randall to the scientific advisory board (SAB). Both bring deep expertise in the advanced science and technology underlying the innovative Duravest portfolio. Earlier this month, the Company announced two initial appointments to its medical advisory board (MAB): Dr. Ron Waksman and Dr. Peter Bonis who have particularly strong experience in clinical trial design, implementation and evaluation.

Alexander Norbash, MD, is Professor and Chairman of the Department of Radiology at Boston University Medical Center. He previously held appointments as Director of Diagnostic and Interventional Neuroradiology at Brigham and Women's Hospital and Associate Professor of Radiology at Harvard Medical School. He is the founding director of the Interventional Neuroradiology and Endovascular Neurosurgery Divisions at Brigham and Women's Hospital, and was formerly an interventional neuroradiologist at the Massachusetts General Hospital. From 1994 through 1998, Dr. Norbash was Director of Head and Neck Imaging and Director of Neuro-Magnetic Resonance Therapy at Stanford University Hospital. Dr. Norbash received his medical degree from the University of Missouri-Kansas City, has a Master's Degree in Healthcare Management from Harvard University, and completed residency at the University of Pittsburgh. His research interests have focused on device development for the treatment of vascular disorders with a concentration on aneurysms, stroke and the treatment of atherosclerotic disease. He has developed several products that are currently in clinical use. Dr. Ogan Gurel - CEO of Duravest - noted that "Dr. Norbash has a truly unique combination of innovative vision and clinical practicality which will be invaluable to both the evaluation and optimization of our investments. We are very privileged to have him as a member of the team." Dr. Norbash added that "The vision of Duravest - its emphasis on safety and its unique position covering interdisciplinary medical technologies - is right on track with trends in medicine. I am very pleased to be a part of a team that clearly will be playing a role in shaping the healthcare of the future.

Lisa Randall, PhD is Professor of Theoretical Physics at Harvard University. Her research concerns the fundamental nature of particles and forces and the relationships among matter's most basic elements. Prof. Randall has worked on a wide variety of models and theories, the most recent of which involve extra dimensions of space. She has also worked on supersymmetry, Standard Model observables, cosmological inflation, baryogenesis, grand unified theories, and aspects of string theory. She has made seminal contributions in all these areas and as of last autumn, was the most cited theoretical physicist of the past five years. Professor Randall earned her PhD from Harvard University and went onto professorships at MIT and Princeton University before returning to Harvard. She is a member of the American Academy of Arts and Sciences, a fellow of the American Physical Society, and is a past winner of an Alfred P. Sloan Foundation Research Fellowship and the Westinghouse (now Intel) Science Talent Search. Dr. Randall commented that "There are as yet unsolved problems in the nature of intermolecular interactions at the protein and nucleic acid level that pertain directly to the effectiveness of pharmaceuticals, drug-device combinations and medical nanotechnology. I am very excited about the possibility of applying the concepts and techniques of advanced physics to these very important questions." Dr. Gurel added that "The appointment of Prof. Randall will add a completely new and valuable dimension to our ability to innovatively as well as rigorously approach the challenges of the future. With Dr. Bonis and Dr. Waksman on our medical advisory board along with Prof. Randall and Dr. Norbash on the scientific advisory board we are prepared to move our portfolio to the highest level."

Background on Duravest, Inc.

Duravest, Inc. (OTC BB:DUVT, XETRA:DUV) seeks innovative and safe medical technologies in their preclinical and breakthrough stages and helps move them toward successful commercialization through key strategic partnerships. Duravest has two subsidiaries - Estracure, Inc. and Bio-Magnetic Therapy Systems, Inc. (BMTS). Estracure is currently developing a next-generation coronary stent based on proprietary estrogen-based technologies which minimize restenosis and potentially prevent progression of coronary lesions. The worldwide coronary stent market was valued at $5.1 billion in 2004 and is estimated to grow to $5.8 billion by 2008. Based on the results of a multi-center Phase II "proof-of-concept" trial in humans and ongoing pig trials, Phase II/III trials with the proprietary 17-beta-estradiol, stent and polymer combination are being currently planned for patient accrual later this year. BMTS- a company with outstanding earnings growth potential, an impeccable balance sheet, no bank debt and both historical and projected positive cash flow - is a leading German-US medical technology firm dedicated to the safe, non-invasive treatment of orthopedic injuries, osteoarthritis and osteoporosis. Each year it is estimated that 2% of the US population incurs a sports-related injury, while 1% of the US population suffers from a work-related injury. For osteoarthritis, it is estimated that by the year 2020, the number of US residents affected will increase from 41 million to more than 59 million (or 19 % of the population). BMTS' proprietary, patented devices based on the PST(TM) technology are in clinical use in Germany with further expansion being planned for the European, Asian and U.S. markets. Duravest is building the future of medicine now to create shareholder value and improve health.

Safe Harbor Forward Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals or assumptions of future events are not statements of historical fact and may be considered forward looking statements. They involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated.